Raymond James Financial Services Advisors, Inc. Galectin Therapeutics Inc Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$1.96 - $2.57 $35,728 - $46,848	-18,229 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.24 - $2.87 $40,832 - $52,317	18,229 New	18,229 $41,000
Q3 2018 Nov 14, 2018	SELL	$3.68 - $6.93 $39,497 - $74,379	-10,733 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$3.16 - $9.16 $33,916 - $98,314	10,733 New	10,733 $68,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.65M

Call Options Held

1.16M

Put Options Held

1.98M

Vanguard Group Inc Valley Forge, PA

2.13M
Shares

$4.12 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.56M
Shares

$3.02 Million
0.0% of portfolio
Advisor Group Holdings, Inc. Phoenix, AZ

1.18M
Shares

$2.28 Million
0.01% of portfolio
Geode Capital Management, LLC Boston, MA

863K
Shares

$1.66 Million
0.0% of portfolio
Commonwealth Equity Services, LLC

483K
Shares

$932,699
0.0% of portfolio

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $115M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account